孤兒藥市場報告（按藥物類型、疾病類型、階段、暢銷藥物、配銷通路和地區分類）2025 年至 2033 年

2024IMARC Group全球孤兒藥市場規模達到 2,373 億美元。

孤兒藥是指用於診斷、預防和治療罕見疾病的藥品。這些藥物是為了滿足特定的公共衛生要求而生產的，而且由於是為一小部分患者生產的，因此通常市場有限。它們對多種腫瘤、代謝、血液、免疫、傳染病和神經疾病有效。淋巴瘤、白血病、囊性纖維化、神經膠質瘤、胰臟癌、卵巢癌、多發性骨髓瘤和腎細胞癌等疾病通常具有生命危險，且是慢性、進行性、退化性和致殘性的，需要針對特定症狀有效的特定治療方案。

孤兒藥市場趨勢：

癌症和其他罕見遺傳疾病的發生率不斷上升是推動市場成長的關鍵因素之一。製藥商正在開發創新的孤兒藥，為患者提供個人化治療。大眾對孤兒藥益處的認知不斷提高，這也推動了市場的發展。新的藥品製造商的出現和政府為抑制傳染病傳播而實施的優惠政策也促進了市場的成長。此外，各種產品創新，如生物孤兒藥的開發，也扮演了其他成長促進因素的角色。這些藥物可以治療癌症等疾病，並逆轉對幹細胞造成的傷害，這極大地促進了它們的整體需求。其他因素，包括醫療保健基礎設施的改善以及廣泛的研究和開發（R&D）活動，預計將進一步推動市場發展。

本報告解答的關鍵問題

• 2024 年全球孤兒藥市場規模？ 2025-2033年全球孤兒藥市場的預期成長率是多少？
• 推動全球孤兒藥市場發展的關鍵因素有哪些？
• COVID-19 對全球孤兒藥市場有何影響？
• 根據藥物類型，全球孤兒藥市場是如何分佈的？
• 根據疾病類型，全球孤兒藥市場如何分佈？
• 根據最暢銷藥物，全球孤兒藥市場如何分佈？
• 根據配銷通路，全球孤兒藥市場分佈如何？
• 全球孤兒藥市場的主要區域有哪些？
• 全球孤兒藥市場的主要參與者/公司有哪些？

目錄

第 1 章：前言

第 2 章：範圍與方法

• 研究目標
• 利害關係人
• 資料來源
  • 主要來源
  • 次要來源
• 市場預測
  • 自下而上的方法
  • 自上而下的方法
• 預測方法

第 3 章：執行摘要

第 4 章：簡介

• 概述
• 主要行業趨勢

第 5 章：全球孤兒藥市場

• 市場概況
• 市場表現
• COVID-19 的影響
• 市場預測

第 6 章：市場區隔：依藥物類型

• 生物
  • 市場趨勢
  • 市場預測
• 非生物
  • 市場趨勢
  • 市場預測

第7章：市場區隔：依疾病類型

• 腫瘤學
  • 市場趨勢
  • 市場預測
• 血液學
  • 市場趨勢
  • 市場預測
• 神經病學
  • 市場趨勢
  • 市場預測
• 心血管
  • 市場趨勢
  • 市場預測
• 其他
  • 市場趨勢
  • 市場預測

第 8 章：市場區隔：依階段

• 第一階段
  • 市場趨勢
  • 市場預測
• 第二階段
  • 市場趨勢
  • 市場預測
• 第三階段
  • 市場趨勢
  • 市場預測
• 第四階段
  • 市場趨勢
  • 市場預測

第 9 章：市場區隔：按暢銷藥物

• 來那度胺
  • 市場趨勢
  • 市場預測
• 利妥昔單抗
  • 市場趨勢
  • 市場預測
• 克帕松
  • 市場趨勢
  • 市場預測
• 奧狄沃
  • 市場趨勢
  • 市場預測
• 可瑞達 (Keytruda)
  • 市場趨勢
  • 市場預測
• 依魯替尼
  • 市場趨勢
  • 市場預測
• 艾沃尼克斯
  • 市場趨勢
  • 市場預測
• 森西帕爾
  • 市場趨勢
  • 市場預測
• 索立利
  • 市場趨勢
  • 市場預測
• 其他
  • 市場趨勢
  • 市場預測

第 10 章：市場區隔：按配銷通路

• 醫院藥房
  • 市場趨勢
  • 市場預測
• 零售藥局
  • 市場趨勢
  • 市場預測
• 線上商店
  • 市場趨勢
  • 市場預測
• 其他
  • 市場趨勢
  • 市場預測

第 11 章：市場區隔：按地區

• 北美洲
  • 美國
  • 加拿大
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 韓國
  • 澳洲
  • 印尼
  • 其他
• 歐洲
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 其他
• 中東和非洲
  • 市場趨勢
  • 市場區隔：依國家
  • 市場預測

第 12 章：SWOT 分析

• 概述
• 優勢
• 弱點
• 機會
• 威脅

第 13 章：價值鏈分析

第 14 章：波特五力分析

• 概述
• 買家的議價能力
• 供應商的議價能力
• 競爭程度
• 新進入者的威脅
• 替代品的威脅

第 15 章：價格分析

第 16 章：競爭格局

• 市場結構
• 關鍵參與者
• 關鍵參與者簡介
  • AbbVie Inc.
  • Alexion Pharmaceuticals Inc.
  • Amgen Inc.
  • Biogen Inc.
  • Bristol Myers Squibb Company
  • F. Hoffmann-La Roche AG (Roche Holding AG)
  • Jazz Pharmaceuticals Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd

The global orphan drugs market size reached USD 237.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 582.5 Billion by 2033, exhibiting a growth rate (CAGR) of 9.97% during 2025-2033.

Orphan drugs refer to pharmaceutical products used for the diagnosis, prevention and treatment of rare medical disorders. These drugs are manufactured to meet a specific public health requirement and usually have a limited market as they are produced for a small group of patients. They are effective against numerous oncological, metabolic, hematologic, immunologic, infectious and neurological diseases. Medical ailments, such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma and renal cell carcinoma, are often life-threatening, chronic, progressive, degenerative and disabling and require specific treatment alternatives that are effective for their particular symptoms.

Orphan Drugs Market Trends:

The increasing prevalence of cancer and other rare genetic disorders is one of the key factors driving the growth of the market. Pharmaceutical manufacturers are developing innovative orphan drugs to provide personalized therapy to patients. The market is also being driven by increasing awareness among the masses regarding the benefits of orphan drugs. The emergence of new pharmaceutical drug manufacturers and the implementation of favorable government policies to inhibit the spread of contagious diseases are also contributing to the market growth. Additionally, various product innovations, such as the development of biological orphan drugs, are acting as other growth-inducing factors. These drugs can treat diseases, such as cancer, and reverse the damage caused to the stem cells, which is facilitating their overall demand significantly. Other factors, including improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities, are expected to drive the market further.

Key Market Segmentation:

Breakup by Drug Type:

• Biological
• Non-Biological

Breakup by Disease Type:

• Oncology
• Hematology
• Neurology
• Cardiovascular
• Others

Breakup by Phase:

• Phase I
• Phase II
• Phase III
• Phase IV

Breakup by Top Selling Drugs:

• Revlimid
• Rituxan
• Copaxone
• Opdivo
• Keytruda
• Imbruvica
• Avonex
• Sensipar
• Soliris
• Others

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Stores
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Jazz Pharmaceuticals Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

• 1.What was the size of the global orphan drugs market in 2024?
• 2.What is the expected growth rate of the global orphan drugs market during 2025-2033?
• 3.What are the key factors driving the global orphan drugs market?
• 4.What has been the impact of COVID-19 on the global orphan drugs market?
• 5.What is the breakup of the global orphan drugs market based on the drug type?
• 6.What is the breakup of the global orphan drugs market based on the disease type?
• 7.What is the breakup of the global orphan drugs market based on top selling drugs?
• 8.What is the breakup of the global orphan drugs market based on the distribution channel?
• 9.What are the key regions in the global orphan drugs market?
• 10.Who are the key players/companies in the global orphan drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Orphan Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Drug Type

• 6.1 Biological
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Non-Biological
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Disease Type

• 7.1 Oncology
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Hematology
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Neurology
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Cardiovascular
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Phase

• 8.1 Phase I
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Phase II
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Phase III
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Phase IV
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Top Selling Drugs

• 9.1 Revlimid
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Rituxan
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Copaxone
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Opdivo
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Keytruda
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast
• 9.6 Imbruvica
  • 9.6.1 Market Trends
  • 9.6.2 Market Forecast
• 9.7 Avonex
  • 9.7.1 Market Trends
  • 9.7.2 Market Forecast
• 9.8 Sensipar
  • 9.8.1 Market Trends
  • 9.8.2 Market Forecast
• 9.9 Soliris
  • 9.9.1 Market Trends
  • 9.9.2 Market Forecast
• 9.10 Others
  • 9.10.1 Market Trends
  • 9.10.2 Market Forecast

10 Market Breakup by Distribution Channel

• 10.1 Hospital Pharmacies
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Retail Pharmacies
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Online Stores
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Others
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 AbbVie Inc.
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
    • 16.3.1.3 Financials
    • 16.3.1.4 SWOT Analysis
  • 16.3.2 Alexion Pharmaceuticals Inc.
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
    • 16.3.2.3 Financials
    • 16.3.2.4 SWOT Analysis
  • 16.3.3 Amgen Inc.
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
    • 16.3.3.3 Financials
    • 16.3.3.4 SWOT Analysis
  • 16.3.4 Biogen Inc.
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
    • 16.3.4.3 Financials
    • 16.3.4.4 SWOT Analysis
  • 16.3.5 Bristol Myers Squibb Company
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
    • 16.3.5.3 Financials
    • 16.3.5.4 SWOT Analysis
  • 16.3.6 F. Hoffmann-La Roche AG (Roche Holding AG)
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
    • 16.3.6.3 SWOT Analysis
  • 16.3.7 Jazz Pharmaceuticals Plc
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
    • 16.3.7.3 Financials
    • 16.3.7.4 SWOT Analysis
  • 16.3.8 Johnson & Johnson
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
    • 16.3.8.3 Financials
    • 16.3.8.4 SWOT Analysis
  • 16.3.9 Merck & Co. Inc.
    • 16.3.9.1 Company Overview
    • 16.3.9.2 Product Portfolio
    • 16.3.9.3 Financials
    • 16.3.9.4 SWOT Analysis
  • 16.3.10 Novartis AG
    • 16.3.10.1 Company Overview
    • 16.3.10.2 Product Portfolio
    • 16.3.10.3 Financials
    • 16.3.10.4 SWOT Analysis
  • 16.3.11 Pfizer Inc.
    • 16.3.11.1 Company Overview
    • 16.3.11.2 Product Portfolio
    • 16.3.11.3 Financials
    • 16.3.11.4 SWOT Analysis
  • 16.3.12 Sanofi S.A.
    • 16.3.12.1 Company Overview
    • 16.3.12.2 Product Portfolio
    • 16.3.12.3 Financials
    • 16.3.12.4 SWOT Analysis
  • 16.3.13 Takeda Pharmaceutical Company Limited
    • 16.3.13.1 Company Overview
    • 16.3.13.2 Product Portfolio
    • 16.3.13.3 Financials
    • 16.3.13.4 SWOT Analysis
  • 16.3.14 Teva Pharmaceutical Industries Ltd
    • 16.3.14.1 Company Overview
    • 16.3.14.2 Product Portfolio
    • 16.3.14.3 Financials
    • 16.3.14.4 SWOT Analysis

List of Figures

• Figure 1: Global: Orphan Drugs Market: Major Drivers and Challenges
• Figure 2: Global: Orphan Drugs Market: Sales Value (in Billion USD), 2019-2024
• Figure 3: Global: Orphan Drugs Market: Breakup by Drug Type (in %), 2024
• Figure 4: Global: Orphan Drugs Market: Breakup by Disease Type (in %), 2024
• Figure 5: Global: Orphan Drugs Market: Breakup by Phase (in %), 2024
• Figure 6: Global: Orphan Drugs Market: Breakup by Top Selling Drugs (in %), 2024
• Figure 7: Global: Orphan Drugs Market: Breakup by Distribution Channel (in %), 2024
• Figure 8: Global: Orphan Drugs Market: Breakup by Region (in %), 2024
• Figure 9: Global: Orphan Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
• Figure 10: Global: Orphan Drugs (Biological) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 11: Global: Orphan Drugs (Biological) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 12: Global: Orphan Drugs (Non-Biological) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 13: Global: Orphan Drugs (Non-Biological) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 14: Global: Orphan Drugs (Oncology) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 15: Global: Orphan Drugs (Oncology) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 16: Global: Orphan Drugs (Hematology) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 17: Global: Orphan Drugs (Hematology) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 18: Global: Orphan Drugs (Neurology) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 19: Global: Orphan Drugs (Neurology) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 20: Global: Orphan Drugs (Cardiovascular) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 21: Global: Orphan Drugs (Cardiovascular) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 22: Global: Orphan Drugs (Other Disease Types) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 23: Global: Orphan Drugs (Other Disease Types) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 24: Global: Orphan Drugs (Phase I) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 25: Global: Orphan Drugs (Phase I) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 26: Global: Orphan Drugs (Phase II) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 27: Global: Orphan Drugs (Phase II) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 28: Global: Orphan Drugs (Phase III) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 29: Global: Orphan Drugs (Phase III) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 30: Global: Orphan Drugs (Phase IV) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 31: Global: Orphan Drugs (Phase IV) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 32: Global: Orphan Drugs (Revlimid) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 33: Global: Orphan Drugs (Revlimid) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 34: Global: Orphan Drugs (Rituxan) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 35: Global: Orphan Drugs (Rituxan) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 36: Global: Orphan Drugs (Copaxone) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 37: Global: Orphan Drugs (Copaxone) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 38: Global: Orphan Drugs (Opdivo) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 39: Global: Orphan Drugs (Opdivo) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 40: Global: Orphan Drugs (Keytruda) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 41: Global: Orphan Drugs (Keytruda) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 42: Global: Orphan Drugs (Imbruvica) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 43: Global: Orphan Drugs (Imbruvica) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 44: Global: Orphan Drugs (Avonex) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 45: Global: Orphan Drugs (Avonex) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 46: Global: Orphan Drugs (Sensipar) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 47: Global: Orphan Drugs (Sensipar) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 48: Global: Orphan Drugs (Soliris) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 49: Global: Orphan Drugs (Soliris) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 50: Global: Orphan Drugs (Other Drugs) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 51: Global: Orphan Drugs (Other Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 52: Global: Orphan Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 53: Global: Orphan Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 54: Global: Orphan Drugs (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 55: Global: Orphan Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 56: Global: Orphan Drugs (Online Stores) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 57: Global: Orphan Drugs (Online Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 58: Global: Orphan Drugs (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 59: Global: Orphan Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 60: North America: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 61: North America: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 62: United States: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 63: United States: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 64: Canada: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 65: Canada: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 66: Asia Pacific: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 67: Asia Pacific: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 68: China: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 69: China: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 70: Japan: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 71: Japan: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 72: India: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 73: India: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 74: South Korea: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 75: South Korea: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 76: Australia: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 77: Australia: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 78: Indonesia: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 79: Indonesia: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 80: Others: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 81: Others: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 82: Europe: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 83: Europe: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 84: Germany: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 85: Germany: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 86: France: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 87: France: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 88: United Kingdom: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 89: United Kingdom: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 90: Italy: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 91: Italy: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 92: Spain: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 93: Spain: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 94: Russia: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 95: Russia: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 96: Others: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 97: Others: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 98: Latin America: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 99: Latin America: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 100: Brazil: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 101: Brazil: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 102: Mexico: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 103: Mexico: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 104: Others: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 105: Others: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 106: Middle East and Africa: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 107: Middle East and Africa: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 108: Global: Orphan Drugs Industry: SWOT Analysis
• Figure 109: Global: Orphan Drugs Industry: Value Chain Analysis
• Figure 110: Global: Orphan Drugs Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Orphan Drugs Market: Key Industry Highlights, 2024 and 2033
• Table 2: Global: Orphan Drugs Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
• Table 3: Global: Orphan Drugs Market Forecast: Breakup by Disease Type (in Million USD), 2025-2033
• Table 4: Global: Orphan Drugs Market Forecast: Breakup by Phase (in Million USD), 2025-2033
• Table 5: Global: Orphan Drugs Market Forecast: Breakup by Top Selling Drugs (in Million USD), 2025-2033
• Table 6: Global: Orphan Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
• Table 7: Global: Orphan Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
• Table 8: Global: Orphan Drugs Market Structure
• Table 9: Global: Orphan Drugs Market: Key Players